Dear , 

Predictimmune’s principals see the need for prognostic tests in immune-mediated diseases, such as Crohn’s disease, as patient outcomes vary widely, from aggressive, relapsing disease to quiescent disease, and there are currently no methods to predict which course patients will take. To address this unmet need the PredictImmune-CD test has been developed in the Department of Medicine at Cambridge University. It is a simple whole blood test based on sound biological principles that stratifies patients with Crohn’s disease into aggressive or quiescent groups and has been validated in multiple, independent patient cohorts. The discovery and development of the test was partly funded by The Wellcome Trust who have agreed to further fund a multi-centre clinical study to confirm the benefit of the test in guiding the management of Crohn’s disease.

The Technology

The PredictImmune-CD test measures the expression levels of a disease related gene panel which, when analysed using proprietary software, stratifies patients, at the point of diagnosis, into the aggressive and quiescent disease types. Each disease type has a preferred treatment paradigm and Predictimmune’s prognostic test will ensure that patients receive the most appropriate course of treatment, avoiding excessive side effects from overtreating the quiescent group and excessive morbidity from undertreating the aggressive group. The benefit to the health provider is better patient outcomes with lower side effects and a lower overall cost. The product will be available both as a laboratory testing service and as a kit.

IP

The company has licensed three patent families from Cambridge Enterprise and the technology is further protected by a proprietary algorithm and a large bank of clinical data required for development of the test.

The Opportunity

The incidence of IBD is 1 in 300 people in the developed world and its incidence is rising fast in developing countries. In the UK alone there are about 620,000 sufferers with the cost to the NHS in excess of £1bn annually. This cost is heavily skewed towards relapsing patients and given the low mortality rates and a median age at diagnosis under 30 this represents a long-term cost burden to society.

PredictImmune will develop similar predictive tests for other significant diseases which fall into the same immune-mediated category, including Lupus, Multiple Sclerosis, Diabetes Mellitus, Rheumatoid Arthritis and Transplantation complications. These all pose long-term burdens on patients and on society and represent very significant market potential for better prognosis technology.

The Team

Dr Tito Bacarese-Hamilton, CEO and Founder, has a proven track record transforming innovative technology into revenue generating platforms spanning start-ups to blue-chip multinationals. He was Head of Development at J&J’s Diabetes Care franchise where he was responsible for the launch of test platforms generating > $2BB per annum. He was also CTO of EKF Diagnostics Holdings plc and CEO/co-Founder of Microtest Matrices, and has held senior management positions at Ares-Serono and Amersham International. He is a Fellow of the American National Association of Clinical Biochemistry and has published more than 50 peer-reviewed articles.  He graduated from King's College, London and earned his PhD at the Royal Postgraduate Medical Centre in London.

Professor Kenneth Smith, CMO and Founder, is Professor of Medicine and Head of the Department of Medicine at the University of Cambridge. Professor Smith is a member of the Scientific Advisory Boards of Medimmune, UCB Celltech and Kymab. He established the Cambridge Immunology Strategic Network, directs the FoCIS Cambridge International Centre of Excellence, and led a recent successful bid for funding to build the Cambridge Institute for Therapeutic Immunology and Infectious Disease, due to open in 2018.

Dr Eoin McKinney, CSO and Founder, is a Wellcome-Beit intermediate research fellow in the Dept. Medicine at the University of Cambridge and an honorary consultant in nephrology and transplantation in Cambridge University NHS hospitals Foundation Trust. He has a first in pre-clinical medicine from Oxford University, then graduated in clinical medicine from Edinburgh University and earned his PhD from Cambridge University.

Dr Paul Lyons, VP Platform Delivery and Founder, is a Principal Research Associate at the Department of Medicine, Cambridge University. He has over 25 years of experience in molecular and cellular biology including senior scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the MRC Rosalind Franklin Centre for Genomics Research.

The Outlook

Predictimmune has carried out considerable market research into the medical need for the tests and the health economic benefits that they will deliver. They have also performed two clinical studies which have validated the test and patents have been filed in all major territories including the EU and US. The plan is to start generating revenues with the PredictImmune-CD test by year end 2017.

We are confident that the management team are in a good position to utilise the strength of the academic team and their research to break new ground in the treatment of these immune-mediated conditions.

This financial promotion is issued by Parkwalk Advisors Limited (Parkwalk), which is authorised and regulated by the Financial Conduct Authority. Investments referred to in this newsletter are not suitable for all investors.  Interested parties are strongly recommended to seek specialist financial and tax advice before investing in any product.  Capital is at risk and investors may not get back the full amount invested. Tax treatment depends on the individual circumstances of each investor and may be subject to change. Past performance is not a reliable indicator of future results, and the value of investments may go down as well as up. Projections and forecasts are also not a reliable indicator of future performance. Investments in small and unquoted companies carry a higher risk than many other forms of investment. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum. Parkwalk is not able to provide advice as to the suitability of investing in any product.